Shopping Cart
Remove All
Your shopping cart is currently empty
COX-2-IN-55 (compound 1) is an orally active Celecoxib analogue with broad-spectrum anticancer properties and relatively weak COX-2 inhibition. It specifically inhibits SERCA2, leading to increased caspase-3 cleavage and DR5 levels, which activates GRP78 and suppresses the progression of triple-negative breast cancer (TNBC). Additionally, COX-2-IN-55 downregulates the angiogenesis markers VEGF-α and IL-8, thereby inhibiting microvessel formation.


| Description | COX-2-IN-55 (compound 1) is an orally active Celecoxib analogue with broad-spectrum anticancer properties and relatively weak COX-2 inhibition. It specifically inhibits SERCA2, leading to increased caspase-3 cleavage and DR5 levels, which activates GRP78 and suppresses the progression of triple-negative breast cancer (TNBC). Additionally, COX-2-IN-55 downregulates the angiogenesis markers VEGF-α and IL-8, thereby inhibiting microvessel formation. |
| In vitro | COX-2-IN-55 (compound 1) inhibits the viability of MDA-MB-231, MDA-MB-468, 4T1, T47D, and MCF-7 cells, with EC50 values of 14.99 μM, 14.26 μM, 11.23 μM, 17.3 μM, and 25.02 μM, respectively. |
| In vivo | COX-2-IN-55, administered at 25 mg/kg/day and 50 mg/kg/day orally for 28 days, exhibits significant antitumor activity in the MDA-MB-231 xenograft model using nu/nu nude mice, achieving up to 85% tumor regression. At a dosage of 100 mg/kg/day, COX-2-IN-55 does not cause notable biochemical or histological toxicity in mice after 48 days of treatment. |
| Molecular Weight | 486.51 |
| Formula | C24H21F3N4O2S |
| Cas No. | 2649115-80-8 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.